Astex announces drug discovery alliance with Boehringer Ingelheim
Cambridge, UK. Astex Technology, the fragment-based drug discovery company, announced a three year, multi-target-based, alliance with Boehringer Ingelheim for the discovery of novel drugs for various therapeutic indications. This new collaboration, will apply Astex's proprietary fragment based discovery approach, Pyramid(TM), to generate novel lead series against targets selected by Boehringer Ingelheim. Boehringer Ingelheim will be responsible for all clinical development and has an option to obtain worldwide exclusive marketing rights for all identified compounds.
Under the terms of the agreement, Boehringer Ingelheim will make an upfront payment to Astex for access to its Pyramid(TM) technology, will fund the research programmes and will provide milestone payments plus royalties based on the sales of approved products.
"We are delighted that Boehringer Ingelheim has chosen Astex for this significant collaboration," commented Timothy Haines, Chief Executive of Astex. "This provides further validation of Astex's world-leading position in fragment-based drug discovery, and underscores the potential of our Pyramidä approach for developing novel lead compounds against important disease-related targets."
Professor Dieter Hinzen, Head of R&D at Boehringer Ingelheim Pharma GmbH & Co. KG, Germany, said "Astex's fragment based Pyramid(TM) approach nicely complements our internal technology portfolio for the discovery and optimization of lead compounds for targets in areas of unmet therapeutic need. This cooperation underlines BI's commitment as a research driven company to provide innovative drugs to the patient."
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Increased levels of carbon dioxide could threaten zinc and iron levels in plants - Study by BGU researcher and colleagues on most significant health threat from climate change featured in Nature
Inpeco S.p.A. - Mailand, Italy
New discoveries about the origin of the brain’s immune system - Significance for Alzheimer’s, multiple sclerosis and more
Ernst & Young Global Pharmaceutical Report Calls for New Approaches to Address Big Pharma's Challenges - Global Pharmaceutical Report 2004
Revolution in biotechnology: CO2 becomes food - Breakthrough bioprocess turns CO2 and electricity into high-protein food
Popular blood type diet debunked
Protein 'bar code' in spinal fluid could lead to first diagnostic test for Alzheimer's patients, Cornell researchers say
Prof Ian Frazer Appointed to Scientific Advisory Board of Avantogen's Hawaii Biotech, Inc.
Oral drug blocks SARS-CoV-2 transmission
